ERBB2 and pachyonychia congenita: In this regard, we interrogated the downstream disease targets that are associated or linked to HER2/erythroblastic oncogene B receptor tyrosine kinase 2 (ERBB2) (shown in Figure 1 and Supplementary Data S1), and we evaluated the frequency of genetic alterations of ERBB2 in PC compared to other cancers (Figure 2).